Researchers studying pancreatic cancer plan to test a new antibodyResearchers studying pan
Posted 18 May 2017 - 05:21 AM
Posted 31 December 2017 - 06:41 AM
Immune cell therapy, the fourth major cancer treatment following surgery, radiotherapy, and chemotherapy, has been recognized as the most active and promising treatment in the comprehensive tumor treatment in the 21st century. It is the only hopeful means to completely kill the tumor cell nowadays. As the most effective cells in the human body to fight the tumor antigen-specific, T cells can pinpoint and target tumor cells. TCR T cell service uses antigen-specific T cells to transfect the tumor specific TCR into the patient's T cells to help identify and kill tumor cells T cells. This tcr technology has a promising application prospect of solid tumors of which NY-ESO-1-specific TCR-T has achieved very significant results in the clinical practice of early solid tumor. For the patients with relapsed NY-ESO-1 positive adult T cell leukemia/lymphoma after HSCT, the allogeneic T cells transduced with a tumor-specific TCR by siTCR vector presented increased tumor-reactivity while GVHD potential is diminishing.